Literature DB >> 29844203

Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia.

Anne Sophie Kubasch1,2, Rebekka Wehner3,4,5,6, Serena Bazzurri7, Antje Tunger3,4, Sebastian Stasik2, Marlene Garzarolli8, Jörn Meinel9, Gustavo Baretton4,5,6,9, Friedegund Meier4,5,6,8, Christian Thiede2,4,5,6, Marc Schmitz3,4,5,6, Uwe Platzbecker1,2,4,5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29844203      PMCID： PMC5998917          DOI： 10.1182/bloodadvances.2017014811

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  19 in total

Review 1.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 2.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

3.  Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.

Authors:  R Coleman Lindsley; Brenton G Mar; Emanuele Mazzola; Peter V Grauman; Sarah Shareef; Steven L Allen; Arnaud Pigneux; Meir Wetzler; Robert K Stuart; Harry P Erba; Lloyd E Damon; Bayard L Powell; Neal Lindeman; David P Steensma; Martha Wadleigh; Daniel J DeAngelo; Donna Neuberg; Richard M Stone; Benjamin L Ebert
Journal:  Blood       Date:  2014-12-30       Impact factor: 22.113

4.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors:  Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

5.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

6.  Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia.

Authors:  Xiangli Chen; Shuhu Liu; Liancai Wang; Wanggang Zhang; Yuqiang Ji; Xiaorong Ma
Journal:  Cancer Biol Ther       Date:  2008-05       Impact factor: 4.742

Review 7.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Authors:  Suzanne L Topalian; Janis M Taube; Robert A Anders; Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

8.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 9.  The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.

Authors:  Li Shi; Shaohua Chen; Lijian Yang; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2013-09-30       Impact factor: 17.388

10.  An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants.

Authors:  S Stasik; C Schuster; C Ortlepp; U Platzbecker; M Bornhäuser; J Schetelig; G Ehninger; G Folprecht; C Thiede
Journal:  Biomol Detect Quantif       Date:  2018-01-09
View more
  3 in total

1.  The wolf of hypomethylating agent failure: what comes next?

Authors:  Anne Sophie Kubasch; Uwe Platzbecker
Journal:  Haematologica       Date:  2019-08       Impact factor: 9.941

Review 2.  Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML.

Authors:  Anne Sophie Kubasch; Uwe Platzbecker
Journal:  Cancers (Basel)       Date:  2018-05-24       Impact factor: 6.639

3.  Old Dogs, New Tricks: Revisiting Immune Modulatory Approaches for Myelodysplastic Syndromes.

Authors:  Katharina S Götze; Uwe Platzbecker
Journal:  Hemasphere       Date:  2018-11-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.